April 27, 2020 / 4:10 AM / a month ago

BRIEF-Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data For Stro-002 Antibody-Drug Conjugate In Ovarian Cancer

April 27 (Reuters) - Sutro Biopharma Inc:

* ANNOUNCES ENCOURAGING INTERIM PHASE 1 CLINICAL DATA FOR A DOSE ESCALATION STUDY OF STRO-002 ANTIBODY-DRUG CONJUGATE IN OVARIAN CANCER

* 89% OF ADVERSE EVENTS WERE GRADE 1 OR 2

* STRO-002 WAS GENERALLY WELL-TOLERATED

* WE PLAN TO SHARE ADDITIONAL DATA ON EFFICACY AND SAFETY OF STRO-002 BY END OF 2020

* A DOSE EXPANSION PHASE OF THIS TRIAL IS PLANNED TO COMMENCE IN SECOND HALF OF 2020

* ALTHOUGH MAXIMUM TOLERATED DOSE HAS NOT BEEN REACHED, SUTRO IS CONTINUING TO ACTIVELY EXPLORE 5.2 MPK TO 6.0 MPK DOSE LEVELS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below